1,4-substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction

US11396496B2 · kind B2 · utility

Assignee

• The Board of Trustees of the University of Illinois · US

Inventors

• Terry Moore · Mountain View, US
• Phillip Lazzara · Chicago, US
• Brian J. David · Falls Church, US
• Benjamin Richardson · Boerne, US
• Atul D. Jain · Chicago, US

Key dates

• Filing date: Apr 2, 2019
• Grant date: Jul 26, 2022
• Expiry date: Apr 2, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed herein are compounds that can act as inhibitors of the Kelch-like ECH-associated protein 1/nuclear factor (erythroid-derived 2)-like 2 (“KEAP1/NRF2”) protein-protein interaction, and methods of using the compounds to treat and prevent diseases and disorders, such as COPD, multiple sclerosis, and diabetes, and in the promotion of wound healing. The compounds described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: formula (I), wherein the substituents are as described.